HSP70-driven molecular response to the proteasome machinery inhibition is a vulnerability in cancer
收藏NIAID Data Ecosystem2026-05-10 收录
官方服务：
资源简介：
Two human primary fibroblast cell lines indicated in the file names were either treated with carfilzomib (C) at the concentrations near the IC50 of proteasome activity (10nM) for 24h, or with DMSO (D) as a control, in biological duplicates (numbers 1-2).
创建时间：
2025-10-29
